Background Blueberries are dietary sources of polyphenols, specifically anthocyanins. Anthocyanins have been identified as having a strong association with type 2 diabetes risk reduction; however, to date few human clinical trials have evaluated the potential beneficial health effects of blueberries in populations with type 2 diabetes. Objectives We investigated the effects of blueberry consumption for 8 wk on cardiometabolic parameters in men with type 2 diabetes. Methods In a double-blind, parallel-arm, randomized controlled trial, 52 men who are US veterans [mean baseline characteristics: age, 67 y (range: 51–75 y); weight, 102 kg (range: 80–130 kg); BMI (in kg/m2), 34 (range: 26–45)] were randomly assigned to 1 of 2 intervention groups. The interventions were either 22 g freeze-dried blueberries or 22 g placebo. The study participants were asked to consume 11 g freeze-dried blueberries or placebo with each of their morning and evening meals along with their typical diet. Results Mean ± SE hemoglobin A1c (7.1% ± 0.1% compared with 7.5% ± 0.2%; P = 0.03), fructosamine (275.5 ± 4.1 compared with 292.4 ± 7.9 µmol/L; P = 0.04), triglycerides (179.6 ± 10.1 compared with 199.6 ± 19.9 mg/dL; P = 0.03), aspartate transaminase (23.2 ± 1.4 compared with 30.5 ± 2.7 units/L; P = 0.02), and alanine transaminase (35.6 ± 1.5 compared with 48.3 ± 2.9 units/L; P = 0.0003) were significantly lower for those consuming blueberries for 8 wk than for those consuming the placebo. Fasting plasma glucose concentrations; serum insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, and C-reactive protein concentrations; blood pressure; and body weight were not significantly different after 8 wk consumption of blueberries compared with the placebo. Conclusions Consumption of 22 g freeze-dried blueberries for 8 wk may beneficially affect cardiometabolic health parameters in men with type 2 diabetes. This trial was registered at clinicaltrials.gov as NCT02972996.
Objectives The study investigated the effects of blueberry consumption on biomarkers of glycemic control in US veterans with type 2 diabetes. Methods In a double-blind, placebo-controlled parallel study, fifty-five men (mean baseline characteristics: 67 years; weight, 103 kg; body mass index, 34 kg/m2) with type 2 diabetes were randomly assigned to 1 of 2 treatment groups for 8 weeks. The treatment groups were either 22 g of a freeze-dried whole blueberry powder (equivalent to 1 cup of fresh blueberries; containing 845 mg phenolics and 470 mg anthocyanins) or 22 g of a blueberry placebo treatment (matched in energy and carbohydrate content to the blueberry treatment). The study participants were asked to consume 11 g of freeze-dried (equivalent to ½ cup of fresh blueberries) blueberry powder or placebo, reconstituted with 240 ml water, with their morning and evening meals along with their typical diet. Fasting blood samples were collected at the beginning and at the end of the study. Results Fructosamine (275.5 ± 4.1 µmol/L vs. 292.4 ± 7.9 µmol/L, respectively; P = 0.04) and hemoglobin A1C (7.1 ± 0.1% vs. 7.5 ± 0.2%, respectively; P = 0.03) were significantly lower for study participants consuming blueberries for 8 weeks compared with the placebo. In addition, triglycerides (160.6 ± 13.1 mg/dl vs. 183.9 ± 10.7 mg/dl, respectively; P = 0.03), aspartate transaminase (AST) (23.2 ± 1.4 units/L vs. 30.5 ± 2.7 units/L, respectively; P = 0.02) and alanine transaminase (ALT) (35.6 ± 1.5 units/L vs. 48.3 ± 2.9 units/L, respectively; P = 0.0003), were significantly lower for those consuming blueberries compared with the placebo. Glucose, insulin, total cholesterol, LDL cholesterol, HDL cholesterol and body weight were not significantly different after 8 weeks of consumption of blueberries compared with the placebo. Conclusions Consumption of 22 g of freeze-dried blueberries daily for 8 weeks results in better glycemic control, such as lowering of fructosamine and hemoglobin A1C. These results along with lower triglyceride concentrations show improvement in the liver enzymes, AST and ALT, which may beneficially affect the cardiometabolic health status of men with type 2 diabetes. Funding Sources The U.S. Highbush Blueberry Council; the study is the result of work supported with resources and the use of facilities at the Stratton VA Medical Center, Albany, NY, USA.
patients and their relatives need to understand how to best control for phosphorous and this can only be done through continuous nutrition education. The Authors are waiting on the results of phosphorus levels for the next 3 months. The Authors would like to thank Baxter Healthcare for its organizational support.http://dx.Obesity is an independent risk factor for development and progression of diabetic kidney disease (DKD). Whether weight loss provides any additional benefit beyond blood pressure (BP) control is unclear. To simulate a trial, we used the Archimedes model, a person-specific simulation model including detailed representations of physiology, diseases, and health care systems. Our population-based sample represented individuals diagnosed with type 2 diabetes and DKD drawn from 1999-2006 cohorts of NHANES. Simulations were generated to estimate costs and health outcomes across time for 3 treatment strategies: (1) standard of care (STD); (2) blood pressure control (BP); and (3) BP combined with 5% weight loss (BPWT). BP control represents 3.5%&6% reductions for those with SBP4130 and SBP4140, respectively. Over a 20y time horizon, discounted costs for the STD group were $165,261 with discounted quality adjusted life-years (QALYs) of 5.89. With BP estimated at $30/month, the incremental cost-effectiveness ratio (ICER) was $26,626/QALY compared to STD. With BPWT at $50/month, the ICER was $31,773 compared to STD. Even with varying intervention costs and durations ( Figure), the ICERs remained favorable, especially for the BPWT group.In conclusion, weight loss in addition to BP control appears to provide favorable value, particularly over moderate time horizons.http://dx.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.